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ABSTRACT
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a progressive inherited heart disease
characterized by ventricular arrhythmias and sudden cardiac death especially in the young. ARVC has
been traditionally associated with the Mediterranean basin, as many seminal studies on the disease
have originated from research groups of this region. Today, however, numerous ARVC registries from all
over the world emphasize that the disease does not have a specific racial or geographical predilection.
This work provides a review on the global perspective of ARVC.
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INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable cardiac muscle disease
characterized pathologically by fibrofatty replacement –usually but not exclusively- of the right
ventricular (RV) myocardium. The estimated prevalence of ARVC is 1:2500 to 1:5000 with male
predominance [1]. The disease shows a familial pattern in 40–70% of the cases and molecular genetic
studies demonstrated that ARVC is a desmosomal disease resulting from genetically defective cell
adhesion proteins such as plakoglobin, desmoplakin, plaokophillin-2, desmoglein-2, and desmocollin
[2,3]. Clinical manifestations are related to electrical instability, including either ventricular tachycardia
of RV origin or ventricular fibrillation, which may lead to sudden cardiac death (SCD), mostly in young
people and athletes [4–6]. In rare cases, the progressive loss of ventricular myocardium may lead to
right ventricular or biventricular heart failure [4].
ARVC had been traditionally associated with the Mediterranean region, as many seminal studies had
originated from research groups in France, Greece, and Italy. Today, however, numerous ARVC
registries from all over the world emphasize that the disease does not have a specific racial or
geographical predilection. This work aims to provide a review on the global perspective of ARVC.
HISTORICAL REVIEW
Giovanni Maria Lancisi (1654–1720) was an anatomist, clinician, epidemiologist, advisor to Pope
Clement XI and one of the greatest Italian physicians of the first half of the 18th century (Figure 1). In his
book, De Motu Cordis et Aneurysmatibus, Lancisi reported a four generation family with sudden deaths
and dilatation and aneurysms of the right ventricle [7]. Two hundred and fifty years later, in 1982,
Dr. Frank Marcus (University of Arizona, United States) collaborating with a French group of researchers
described the disease of right ventricular dysplasia in a series of 24 patients and referred to La
Salpetrie`re Hospital and Jean Restand Hospital in Paris from 1973 to 1980. The group characterized
Figure 1. Giovanni Maria Lancisi (1654–1720), an Italian physician, epidemiologist and anatomist. He observed
marked neck venous distension with tricuspid valve insufficiency (later to be known as Lancisi’s sign) and
associated aortic arch aneurysms with syphilis in his masterpiece in cardiac pathology: De Motu Cordis et
Aneurysmatibus (On the motion of the heart and on aneurysms), published posthumously in 1738. In his book,
he also reported the first known family of sudden cardiac death and right ventricular aneurysms [7].
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some of the fundamental clinical elements of the disease including the T wave inversion in the right
precordial leads on the surface electrocardiogram (ECG), the left bundle branch block pattern of the
QRS complex during spontaneous ventricular tachycardia, and the echocardiographic features of a
normal left ventricle with an enlarged and aneurismal right ventricle [8]. In 1986, Protonotarios et al.
studied nine cases of palmoplantar keratosis in the Greek island of Naxos, of which seven showed
symptoms and signs of heart disease. Three cases had episodes of ventricular tachycardia (VT) and
a fourth patient died suddenly. All patients with cardiac signs and symptoms showed
echocardiographic enlargement of the right ventricle and a right ventricular band. Moreover, the left
ventricle was also affected in three patients [9]. The described cardiocutaneous syndrome, coined as
“Naxos disease”, is an autosomal recessive form of ARVC. The current concept of the clinical and
pathological picture of ARVC was established in Padua, Italy. Familial occurrence of ARVC with an
autosomal dominant pattern and incomplete penetrance was proven by Nava et al. in 1988 [10].
Furthermore, Thiene et al. associated the pathology of ARVC with a series of SCD in the young (#35
years), mostly during effort. All the cases had T wave inversion on the right precordial surface ECG at
rest and left bundle branch block QRS pattern during ventricular tachycardia [11]. This was the first time
ARVC was acknowledged as a major cause of death in the young.
In 1994, Rampazzo et al. from the University of Padua, described the first gene locus associated with
ARVC (14q23–24). To locate the disease gene, several polymorphic DNA markers were evaluated. Since
some forms of hypertrophic cardiomyopathy are due to mutations of the b-myosin gene, chromosome
14 was selected as a first candidate for analysis, on the assumption that functionally related genes are
often located on the same chromosome. The investigation was also extended to chromosomes 1, 2, 6,
12, and 17 that were linked to other hypertrophy cardiomyopathy gene mutations [12]. However, in
2000, the discovery that plakoglobin and desmoplakin gene mutations result in the autosomal
recessive cardiocutaneous Naxos and Carvajal syndromes, respectively, led to the association between
ARVC and desmosome gene mutation [13,14]. Desmoplakin was the first defective gene to be
associated with autosomal dominant ARVC in 2002 [15]. Today, mutations in desmoplakin [15,16],
plakoglobin [17], plakophilin-2 [18], desmoglein-2 [19], desmocollin-2 [20] and most recently desmin
[21], have been found in dominant forms of ARVC with double and compound heterozygosity
commonly reported [22,23]. This consistent protein alteration coined the concept of ARVC as a
desmosomal disease in contrast to hypertrophic cardiomyopathy as a sarcomeric disease, and dilated
cardiomyopathy as a cytoskeletal disease.
ARVC AROUND THE WORLD
The current views concerning ARVC have been shaped based on results from vanguard national and
international registries. The last three decades have witnessed an exponential increase in the scientific
contribution to ARVC, not only in the number of published data on ARVC, but also on the number of
centers involved in the research. Today, centers from all corners of the world add significant
contribution to the global understanding of the pathology, molecular, genetics, epidemiology, clinical,
electrophysiology, imaging, risk stratification and management aspects of ARVC.
In Europe, influential works have been published from France, Germany, Greece, Italy, the
Netherlands, Spain and the United Kingdom. Hulot et al. published a study in 2004 on the clinical
course of French patients with ARVC. Data were collected from 130 patients with confirmed ARVC from a
tertiary center between 1977 and 2000. The study population characteristics showed male
predominance (100 men) and a mean age at onset of symptoms of 31.8 ^ 14.4 years. After a mean
follow-up of 8.1 ^ 7.8 years, there were 21 deaths with a cardiovascular origin (progressive heart failure
in 14 patients and sudden death for the remaining 7 patients). All patients who died had a history of
ventricular tachycardia. This shows that the main cause of death in this cohort was not arrhythmic
death but rather congestive HF, highly attributable to the adequate implantable cardioverter-
defibrillator (ICD) therapy in France [24]. From Germany, Wichter et al. published the largest series on
pharmacological therapy in ARVC, first published in 1992 and updated in 2005, comparing multiple
antiarrhythmic drugs and concluding in their 2005 update that sotalol at a dosage of 320–480mg/d
was the most effective drug resulting in a 68% overall efficacy [25,26]. The same group in 2004,
concluded from their single-center experience that there is a marked improvement in long-term
prognosis with ICD therapy in high-risk ARVC patients [27]. The Greek association between the
cutaneous manifestations and the cardiac manifestations in Naxos disease had lead to the association
of ARVC with desmosomal protein abnormalities (Figure 2) [13]. In Italy, an ECG-based pre-participation
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screening program for athletes has been going for more than 30 years. This screening program has
shown marked efficacy in detecting cardiac pathologies leading to SCD in the young, with a drop of
mortality rates among athletes in the Veneto region from 3.5/100,000 in 1979 to 0.5/100,000 in 2003
(Figure 3) [28]. This impressive drop was largely attributable to the successful detection of ARVC and
hypertrophic cardiomyopathy among the screened individuals, as early reports accounted ARVC as the
second most common cause of death in the young in the Veneto region [11]. Moreover, in 2003,
Corrado et al. in the DARVIN I study recruited 132 ARVC patients from 22 institutions in North Italy and
one in the United States, of whom 80% received an ICD implant for sudden cardiac arrest or sustained
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Figure 3. Annual incidence rates of SCD per 100,000 person-years among screened competitive athletes and
unscreened non-athletes aged 12 to 35 in the Veneto region, Italy. Note the sharp decline of the screened athlete
line in red [28].
Figure 2. Clockwise from left: The Greek island of Naxos. A nuclear Naxos disease family. Analysis reveals the
presence of a mutant allele (one bold band) in the homozygous boy and the wild-type (two light bands)
coexisting with the mutant allele in the heterozygous carrier parents. Classic symptoms of Naxos disease,
keratoderma striate in palmar and diffuse in plantar areas in the homozygous boy and wooly hair [41].
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ventricular tachycardia. The group demonstrated that 48% of the patients were saved by at least one
appropriate ICD intervention during the study period of 39 ^ 25 months (Figure 4) [29]. Spanish
football fans were overwhelmed with the tragic death of FC Sevilla midfielder Antonio Peurta in 2007
due to ARVC (Figure 5). This sad incident reflected the study results on the causes of deaths among
athletes in Spain from the period 1995 to 2001, with arrhythmic cardiomyopathies accounting for 16%
of all deaths [30]. A notable paper was published in 2009 on the etiology of sudden cardiac death in
athletes in the UK from 1996 to 2008. It was found that cardiomyopathies are the most common cause
of SCD in young British athletes accounting for 62% with ARVC attributed to 14% of deaths [31].
Along the Mediterranean basin, Naxos disease was described in one family in Turkey [32] and three
Arab Israeli families [33]. With the increased vigilance and physician awareness, many new ARVC cases
have been diagnosed yearly in Egypt (Figure 6). The South African ARVC registry started in 2004, and
published its first results in 2009 on the clinical course of patients with ARVC and PKP 2 mutations.
The characteristics of ARVC in South Africa are similar to those from the French cohort showing a
mean age of presentation of around 40, with male predominance of about 70%, and palpitations and
syncope being the main presenting symptoms. South African researchers discovered five new PKP2
gene mutations causing ARVC (Figure 7). One of these gene mutations was found in four different
unrelated Caucasian families. Dr. Mayosi from the South African group explains this finding as a
founder gene effect, attributed most likely to one of the early Dutch settlers arriving to The Cape of
Good Will [34]. The South African results were in concordance with the results of the Dutch paper on the
prevalence of PKP 2 mutations in patients with ARVC in the Netherlands published in 2006. PKP2 gene
mutations were found in nearly half of all Dutch patients with established ARVC diagnosis. It also
accounted for more than 70% of familial ARVC in the Netherlands [35]. The matching findings of the two
studies miles apart highlight the importance of taking into consideration all historical, ethnic and
anthropological factors when dealing with a genetically determined disease.
Moving to the Far East, Komura and colleagues studied the clinical course of ARVC in a Japanese
cohort of 35 patients. The study subdivided the patients to a group presenting with VT and another
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Figure 4. Kaplan-Meier analysis from DARVIN I study of actual patient survival (upper line) compared with
survival free of ventricular fibrillation/flutter (lower line) that in all likelihood would have been fatal in the
absence of the ICD. The divergence between the lines reflects the estimated mortality reduction by ICD therapy
of 24% at 3 years of follow up [29].
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group presenting with congestive HF. The group with congestive HF presented at a later age of 66 and
carried a worse prognosis with all three patients dying after only 20 months of follow up. The VT group
presented at a younger age of 44 years and carried a better prognosis with only two patients dying after
more than 60 months of follow up. Also, concerning the management of ARVC, patients who were
inserted ICD’s and were controlled on drug therapy did much better than patients sent for RF ablation,
with a higher rate of recurrence of VT within the RF ablation group (Figure 8) [36].
A Chinese group published a cohort of 39 patients with ARVC, sharing almost the same clinical
picture as the South African, French, and Japanese cohorts also including the same outcome of therapy.
Of these patients, 33 were males and 6 were females and the age at first presentation was 34.9 ^ 9.8
years. The most common symptoms were palpitation (62%) and syncope (44%). An interesting
observation of the Chinese cohort was that all seven patients who were inserted an ICD had at least
one appropriate shock [37].
On the other side of the ocean, a large United States registry on ARVC was published in 2005. With a
cohort of 100 patients from the Johns Hopkins registry, the American Working Group concluded that
ARVC patients present between the second and fifth decades of life either with symptoms of
palpitations and syncope associated with ventricular tachycardia or with SCD. Due to genetic
Figure 5. Antonio Jose Puerta Perez (1984–2007), a Spanish midfielder who used to play for FC Sevilla was
affected with ARVC, 3 days after suffering a series of cardiac arrests during a Spanish league game against
Getafe.
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heterogeneity, signs and symptoms can widely vary and diagnosis is often delayed. However, once
diagnosed and treated with an ICD, mortality is low (Figure 9) [38].
ARVC has also been observed in South America. Carvajal et al. from Ecuador published in 1998 a
series of 12 patients presenting with cardiocutaneous syndrome of palmoplanter keratosis and DCM.
This is known as Carvajal syndrome and it has been associated with desmoplakin mutations and
severe left ventricular involvement [14,39]. The magnetic resonance image (MRI) picture of Carvajal
syndrome often mimics that of LV non- compaction. Noteworthy, there have been case reports of
patients with Carvajal syndrome from all over the world which shows that the condition is not exclusive
to the South American population (Figure 10) [40].
In Australia, there is an ongoing major national registry on cardiomyopathies that was initiated in
2009. Another exciting research focus in Australia is the Poll Hereford cattle. It was recently found that
this particular Australian cattle have the same phenotype of Naxos/Carvajal disease with woolly hair
and biventricular fibrosis and sudden death, representing a natural animal model for further studies on
ARVC (Figure 11) [41,42].
The need to set up international registries for ARVC has been recognized in recent years and
many attempts have been accomplished after the publication of the diagnostic Task Force criteria in
1994 [43,44]. A multidisciplinary collaborative European study has been designed with the aim to
investigate the clinical, pathological and genetic features of ARVC. The completed European registry
had been coordinated in Padua and benefited from the contributions of researchers from France,
Germany, Greece, the Netherlands, Poland and the United Kingdom [45]. Simultaneously, another
Figure 6. Above: Surface ECG precordial lead recordings of a 50 year old Egyptian/Sudanese patient showing
Epsilon wave in V1, T wave inversion in V1-3, and relative QRS prolongation in right precordial leads. Below:
Cardiac magnetic resonance imaging demonstrating delayed gadolinium enhancement in the right ventricular
free wall denoting extensive fibrosis. The patient suffered two episodes of sustained ventricular tachycardias
with left bundle branch block pattern with altered level of consciousness. An ICD was implanted for secondary
prevention. (Images courtesy of Mohamed Donya, MD, FRCR, Aswan Heart Centre, Aswan, Egypt).
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major registry in North America was coordinated by Dr. Frank Marcus in collaboration with European
expertise coordinated by Dr. Gaetano Thiene [46].
The labor of these large registries has bared fruit in the form of the updated modified Task Force
criteria for the diagnosis of ARVC, which was published in 2010. With the international community
sharing two decades of knowledge and expertise, the modified Task Force maintained the approach of
classifying the structural, histological, electrocardiographic, arrhythmic, and genetic features of ARVC
into major and minor criteria [43,47]. The new modifications emphasized on quantifying the extent of
RV dysfunction by echocardiography or MRI. Moreover, it was also proposed to characterize the tissue
of the RV wall by evaluating the residual myocytes by morphometric analysis with less than 60% of
residual myocytes as a major criterion. In addition, definite genetic linkage to ARVC–by identification
of a pathogenic mutation categorized as associated or most likely associated with ARVC in the patient
under evaluation–is now considered a major criterion [47].
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C1132T*
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IVS2146-1G>C T2540C*
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Figure 7. Results from the South African registry; Schematic representation of the PKP2 mutations found in the
study. Black boxes indicate the 14 exons of the PKP2 gene. Disease causing mutations are shown above the
exons and polymorphisms are shown below [34].
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Figure 8. The Kaplan-Meier survival curve from the Japanese study. The CHF group showed a significantly higher
mortality rate in comparison to the VT group [36].
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Figure 10. A: Cutaneous features of Carvajal syndrome, including wooly hair, palmoplantar keratosis [39].
B: Cine true fast imaging with steady-state precession image in the short-axis orientation shows dilatation and
a trabecular disarray of both ventricles with the appearance of a noncompaction syndrome. This patient was
found to have Carvajal syndrome postmortem. He was living in Germany at the time of study however, his family
origins were from the city Giresun of Tirebolu near Azerbaijan [40].
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Figure 9. Schematic outline and quantification of the presentation, treatment, arrhythmia, and outcome in the
entire patient population in the John Hopkins Registry. Sx indicates symptoms; Asx, asymptomatic; VF,
ventricular fibrillation; Abl, catheter ablation of VT; Rec VT, recurrent VT; HF, heart failure; and w/o, without.
*These patients died of noncardiac causes of death; autopsy revealed findings consistent with ARVD. †These
patients experienced fatal VF leading to SCD; they could not be resuscitated. ‡This patient died because of
biventricular heart failure at the age of 27 years; an ICD was in place at the time of death and the patient was
awaiting a heart transplant [38].
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SUMMARY
In summary, the scientific research on ARVC clinical course and management has much progressed
over the last 30 years. International collaboration has led to the establishment of diagnostic criteria
and a management plan for patients with ARVC. However, more national and multinational registries
and effective screening programs are still needed to overcome the risk of sudden cardiac death in this
globally recognized cardiomyopathy (Figure 12).
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